{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:39:59Z","timestamp":1790872799354,"version":"4.1.0"},"reference-count":174,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","translationalres.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.trsl.2016.12.007","type":"journal-article","created":{"date-parts":[[2016,12,23]],"date-time":"2016-12-23T16:00:21Z","timestamp":1482508821000},"page":"41-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["HIV and its relationship to insulin resistance and lipid abnormalities"],"prefix":"10.1016","volume":"183","author":[{"given":"Lemuel R.","family":"Non","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerome V.","family":"Escota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Powderly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2016.12.007_bib1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1086\/505147","article-title":"The survival benefits of\u00a0AIDS treatment in the United States","volume":"194","author":"Walensky","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2016.12.007_bib2","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/ije\/dyr164","article-title":"All-cause mortality in treated HIV-infected adults with\u00a0CD4 \u2265500\/mm3 compared with the general population: evidence from a large European observational cohort collaboration","volume":"41","author":"Lewden","year":"2012","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.trsl.2016.12.007_bib3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.7326\/0003-4819-146-2-200701160-00003","article-title":"Survival of persons with and without HIV infection in Denmark, 1995-2005","volume":"146","author":"Lohse","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trsl.2016.12.007_bib4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.7326\/0003-4819-145-6-200609190-00003","article-title":"Causes of death\u00a0among persons with AIDS in the era of highly active antiretroviral therapy: New York City","volume":"145","author":"Sackoff","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trsl.2016.12.007_bib5","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s15010-012-0386-7","article-title":"All-cause mortality in hospitalized HIV-infected patients at an acute tertiary care hospital with a comprehensive outpatient HIV care program in New York City in the era of highly active antiretroviral therapy (HAART)","volume":"41","author":"Kim","year":"2013","journal-title":"Infection"},{"key":"10.1016\/j.trsl.2016.12.007_bib6","doi-asserted-by":"publisher","first-page":"e000174","DOI":"10.1136\/openhrt-2014-000174","article-title":"Cardiovascular disease in HIV patients: from bench to bedside and backwards","volume":"2","author":"Cerrato","year":"2015","journal-title":"Open Heart"},{"key":"10.1016\/j.trsl.2016.12.007_bib7","first-page":"1045","article-title":"Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome","volume":"74","author":"Grunfeld","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.trsl.2016.12.007_bib8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1089\/met.2008.0096","article-title":"Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease","volume":"7","author":"Anuurad","year":"2009","journal-title":"Metab Syndr Relat Disord"},{"key":"10.1016\/j.trsl.2016.12.007_bib9","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S1473-3099(13)70271-8","article-title":"Metabolic disease in HIV infection","volume":"13","author":"Lake","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.trsl.2016.12.007_bib10","first-page":"112","article-title":"Dyslipidemia and its treatment in HIV infection","volume":"18","author":"Grunfeld","year":"2010","journal-title":"Top HIV Med"},{"key":"10.1016\/j.trsl.2016.12.007_bib11","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nri3793","article-title":"Cholesterol, inflammation and innate immunity","volume":"15","author":"Tall","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.trsl.2016.12.007_bib12","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s11904-012-0124-x","article-title":"The burden of diabetes and hyperlipidemia in treated HIV infection and approaches for cardiometabolic care","volume":"9","author":"Samaras","year":"2012","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.trsl.2016.12.007_bib13","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/j.1365-2362.1994.tb02185.x","article-title":"Plasma lipids in HIV-infected patients: a prospective study in 95 patients","volume":"24","author":"Constans","year":"1994","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.trsl.2016.12.007_bib14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.metabol.2005.07.012","article-title":"HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment","volume":"55","author":"Rose","year":"2006","journal-title":"Metabolism"},{"key":"10.1016\/j.trsl.2016.12.007_bib15","first-page":"1149","article-title":"Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation","volume":"7","author":"Zangerle","year":"1994","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.trsl.2016.12.007_bib16","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1468-1293.2005.00273.x","article-title":"Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort","volume":"6","author":"El-Sadr","year":"2005","journal-title":"HIV Med"},{"key":"10.1016\/j.trsl.2016.12.007_bib17","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.metabol.2006.02.024","article-title":"Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy","volume":"55","author":"Estrada","year":"2006","journal-title":"Metabolism"},{"key":"10.1016\/j.trsl.2016.12.007_bib18","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1086\/317541","article-title":"Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy","volume":"32","author":"Hadigan","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trsl.2016.12.007_bib19","unstructured":"WHO|Number of people (all ages) living with HIV. WHO. Published 2016. Available at: http:\/\/www.who.int\/gho\/hiv\/epidemic_status\/cases_all\/en\/. Accessed August 13,\u00a02016."},{"key":"10.1016\/j.trsl.2016.12.007_bib20","unstructured":"Centers for Disease Control and Prevention. Diagnoses of HIV infection in the United States and dependent areas, 2014. HIV Surveill Report, 2014. 2015;26:1\u2013123. Available at: http:\/\/www.cdc.gov\/hiv\/library\/reports\/surveillance\/. Accessed July 5, 2016."},{"key":"10.1016\/j.trsl.2016.12.007_bib21","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1097\/QAD.0000000000001215","article-title":"Chronic health conditions in medicare beneficiaries 65 years and older with HIV infection","volume":"30","author":"Friedman","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.trsl.2016.12.007_bib22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/QAI.0000000000000419","article-title":"HIV infection, cardiovascular disease risk factor profile, and risk for acute myocardial infarction","volume":"68","author":"Paisible","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.trsl.2016.12.007_bib23","doi-asserted-by":"publisher","first-page":"e001035","DOI":"10.1161\/JAHA.114.001035","article-title":"HIV infection and cardiovascular disease in women","volume":"3","author":"Womack","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.trsl.2016.12.007_bib24","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1097\/00126334-200308010-00012","article-title":"Coronary heart disease in HIV-infected individuals","volume":"33","author":"Currier","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.trsl.2016.12.007_bib25","doi-asserted-by":"publisher","first-page":"e2201","DOI":"10.1097\/MD.0000000000002201","article-title":"Prevalence of dyslipidemia among antiretroviral-naive HIV-infected individuals in China","volume":"94","author":"Shen","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.trsl.2016.12.007_bib26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/QAI.0b013e318219a3d1","article-title":"Dyslipidemia in an HIV-positive antiretroviral treatment-naive population in Dar es Salaam, Tanzania","volume":"57","author":"Armstrong","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.trsl.2016.12.007_bib27","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1177\/2325957414555227","article-title":"Dyslipidemia in ART-naive HIV-infected persons in Nigeria\u2013Implications for care","volume":"14","author":"Kuti","year":"2015","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"10.1016\/j.trsl.2016.12.007_bib28","doi-asserted-by":"publisher","first-page":"e0151911","DOI":"10.1371\/journal.pone.0151911","article-title":"Anti-retroviral therapy increases the prevalence of dyslipidemia in South African HIV-infected patients","volume":"11","author":"Dave","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2016.12.007_bib29","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/2325957415614642","article-title":"Lipid profile in HIV-infected patients using first-line antiretroviral drugs","volume":"15","author":"Ombeni","year":"2016","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"10.1016\/j.trsl.2016.12.007_bib30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12872-015-0090-5","article-title":"Highly active antiretroviral therapy and dyslipidemia in people living with HIV\/AIDS in Fako Division, South West Region of Cameroon","volume":"15","author":"Nsagha","year":"2015","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.trsl.2016.12.007_bib31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ijcard.2015.07.052","article-title":"Impact of antiretroviral therapy on serum lipoprotein levels and dyslipidemias: a systematic review and meta-analysis","volume":"199","author":"Nduka","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.trsl.2016.12.007_bib32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/135965350801300215","article-title":"Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial","volume":"13","author":"Phillips","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1016\/j.trsl.2016.12.007_bib33","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/15284336.2016.1207297","article-title":"Severe dyslipidemia and immune activation in HIV patients with dysglycemia","volume":"17","author":"Jin","year":"2016","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.trsl.2016.12.007_bib34","doi-asserted-by":"publisher","first-page":"F167","DOI":"10.1097\/00002030-199815000-00001","article-title":"Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients","volume":"12","author":"Walli","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.trsl.2016.12.007_bib35","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/0026-0495(91)90059-6","article-title":"Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men","volume":"40","author":"Hommes","year":"1991","journal-title":"Metabolism"},{"key":"10.1016\/j.trsl.2016.12.007_bib36","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1001\/jama.1997.03550050039013","article-title":"From the Food and Drug Administration","volume":"278","author":"Nightingale","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.trsl.2016.12.007_bib37","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1001\/jama.2015.4260","article-title":"Prevalence of the metabolic syndrome in the United States, 2003-2012","volume":"313","author":"Aguilar","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.trsl.2016.12.007_bib38","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.2337\/diacare.25.7.1253","article-title":"Prevalence of metabolic syndrome among HIV patients","volume":"25","author":"Gazzaruso","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.trsl.2016.12.007_bib39","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/01.qai.0000219775.20174.2d","article-title":"Metabolic syndrome: a real threat for HIV-positive patients?: Results from the SIMONE study","volume":"42","author":"Bonfanti","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.trsl.2016.12.007_bib40","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1086\/511679","article-title":"Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population","volume":"44","author":"Mondy","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trsl.2016.12.007_bib41","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1258\/095646207780132415","article-title":"Incidence and prevalence of the metabolic syndrome in a cohort of naive HIV-infected patients: prospective analysis at 48 weeks of highly active antiretroviral therapy","volume":"18","author":"Palacios","year":"2007","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.trsl.2016.12.007_bib42","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1097\/QAD.0b013e3282efad32","article-title":"Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection","volume":"21","author":"Wand","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.trsl.2016.12.007_bib43","first-page":"557","article-title":"A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia","volume":"39","author":"Amorosa","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.trsl.2016.12.007_bib44","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1001\/jama.2016.6361","article-title":"Trends in obesity prevalence among children and adolescents in the United States, 1988-1994 through 2013-2014","volume":"315","author":"Ogden","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.trsl.2016.12.007_bib45","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/S0140-6736(16)00618-8","article-title":"Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants","volume":"387","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.trsl.2016.12.007_bib46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2174\/1874192401105010049","article-title":"HIV and HAART-associated dyslipidemia","volume":"5","author":"Feeney","year":"2011","journal-title":"Open Cardiovasc Med J"},{"key":"10.1016\/j.trsl.2016.12.007_bib47","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1001\/jama.289.22.2978","article-title":"Impact of HIV infection and HAART on serum lipids in men","volume":"289","author":"Riddler","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.trsl.2016.12.007_bib48","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1056\/NEJMoa1001689","article-title":"Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis","volume":"364","author":"Khera","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2016.12.007_bib49","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.atherosclerosis.2010.01.011","article-title":"ABC transporters, atherosclerosis and inflammation","volume":"211","author":"Fitzgerald","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.trsl.2016.12.007_bib50","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1371\/journal.pbio.0040365","article-title":"Human immunodeficiency virus impairs reverse cholesterol transport from macrophages","volume":"4","author":"Mujawar","year":"2006","journal-title":"PLoS Biol"},{"key":"10.1016\/j.trsl.2016.12.007_bib51","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1097\/QAD.0000000000000739","article-title":"Monocytes from HIV-infected individuals show impaired cholesterol efflux and increased foam cell formation after transendothelial migration","volume":"29","author":"Maisa","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.trsl.2016.12.007_bib52","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1096\/fj.13-246876","article-title":"HIV protein Nef causes dyslipidemia and formation of foam cells in mouse models of atherosclerosis","volume":"28","author":"Cui","year":"2014","journal-title":"FASEB J"},{"key":"10.1016\/j.trsl.2016.12.007_bib53","doi-asserted-by":"publisher","first-page":"ofu108","DOI":"10.1093\/ofid\/ofu108","article-title":"High-density lipoprotein-mediated cholesterol efflux capacity is improved by treatment with antiretroviral therapy in acute human immunodeficiency virus infection","volume":"1","author":"Lo","year":"2014","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.trsl.2016.12.007_bib54","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1194\/jlr.M054510","article-title":"Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: impact of HAART","volume":"56","author":"El Khoury","year":"2015","journal-title":"J Lipid Res"},{"key":"10.1016\/j.trsl.2016.12.007_bib55","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.atherosclerosis.2015.10.103","article-title":"Lipid metabolism in patients infected with Nef-deficient HIV-1 strain","volume":"244","author":"Low","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.trsl.2016.12.007_bib56","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1210\/me.2007-0124","article-title":"Human immunodeficiency virus (HIV)-1 viral protein R suppresses transcriptional activity of peroxisome proliferator-activated receptor {gamma} and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy","volume":"22","author":"Shrivastav","year":"2008","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.trsl.2016.12.007_bib57","doi-asserted-by":"publisher","first-page":"34268","DOI":"10.1074\/jbc.M300043200","article-title":"Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass","volume":"278","author":"Gavrilova","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.trsl.2016.12.007_bib58","doi-asserted-by":"publisher","first-page":"e3003","DOI":"10.1371\/journal.pone.0003003","article-title":"HIV replication enhances production of free fatty acids, low density lipoproteins and many key proteins involved in lipid metabolism: a proteomics study","volume":"3","author":"Rasheed","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2016.12.007_bib59","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1194\/jlr.R300019-JLR200","article-title":"Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host","volume":"45","author":"Khovidhunkit","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.trsl.2016.12.007_bib60","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/hep.510250632","article-title":"Interferon alpha induces disorder of lipid metabolism by lowering postheparin lipases and cholesteryl ester transfer protein activities in patients with chronic hepatitis C","volume":"25","author":"Shinohara","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.trsl.2016.12.007_bib61","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.metabol.2005.08.018","article-title":"Tumor necrosis factor alpha is associated with insulin-mediated suppression of free fatty acids and net lipid oxidation in HIV-infected patients with lipodystrophy","volume":"55","author":"Haugaard","year":"2006","journal-title":"Metabolism"},{"key":"10.1016\/j.trsl.2016.12.007_bib62","first-page":"559","article-title":"Increased de novo hepatic lipogenesis in human immunodeficiency virus infection","volume":"76","author":"Hellerstein","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.trsl.2016.12.007_bib63","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1161\/CIRCULATIONAHA.108.810721","article-title":"Inflammation impairs reverse cholesterol transport in\u00a0vivo","volume":"119","author":"McGillicuddy","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2016.12.007_bib64","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.mehy.2015.10.013","article-title":"Fatty acyl composition of lysophosphatidylcholine is important in atherosclerosis","volume":"85","author":"Akerele","year":"2015","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.trsl.2016.12.007_bib65","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/ni.1836","article-title":"CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer","volume":"11","author":"Stewart","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.trsl.2016.12.007_bib66","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/ni.2639","article-title":"CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation","volume":"14","author":"Sheedy","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1016\/j.trsl.2016.12.007_bib67","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/QAI.0000000000000566","article-title":"Oxidized LDL levels are increased in HIV infection and may drive monocyte activation","volume":"69","author":"Zidar","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.trsl.2016.12.007_bib68","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1161\/ATVBAHA.111.241869","article-title":"Metabolic syndrome, insulin resistance, and roles of inflammation\u2013mechanisms and therapeutic targets","volume":"32","author":"Romeo","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.trsl.2016.12.007_bib69","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13098-016-0156-2","article-title":"Visceral adiposity syndrome","volume":"8","author":"Lopes","year":"2016","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.trsl.2016.12.007_bib70","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1056\/NEJMra1011035","article-title":"Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease","volume":"371","author":"Shulman","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2016.12.007_bib71","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1086\/586713","article-title":"Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study","volume":"197","author":"Emery","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2016.12.007_bib72","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1097\/QAD.0b013e32834be088","article-title":"Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy","volume":"25","author":"Baker","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.trsl.2016.12.007_bib73","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/B978-0-12-407707-2.00002-3","article-title":"Residual immune dysregulation syndrome in treated HIV infection","volume":"119","author":"Lederman","year":"2013","journal-title":"Adv Immunol"},{"key":"10.1016\/j.trsl.2016.12.007_bib74","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/COH.0000000000000019","article-title":"Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients","volume":"9","author":"Funderburg","year":"2014","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.trsl.2016.12.007_bib75","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/QAI.0000000000000559","article-title":"Viremic and virologically suppressed HIV infection increases age-related changes to monocyte activation equivalent to 12 and 4 Years of aging, respectively","volume":"69","author":"Angelovich","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.trsl.2016.12.007_bib76","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1089\/aid.2014.0239","article-title":"Characterization of lipid composition and high-density lipoprotein function in HIV-infected individuals on stable antiretroviral regimens","volume":"31","author":"Munger","year":"2015","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.trsl.2016.12.007_bib77","first-page":"201027","article-title":"Hypertriglyceridemia, metabolic syndrome, and cardiovascular disease in HIV-infected patients: effects of antiretroviral therapy and adipose tissue distribution","volume":"2012","author":"van Wijk","year":"2012","journal-title":"Int J Vasc Med"},{"key":"10.1016\/j.trsl.2016.12.007_bib78","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12916-016-0625-3","article-title":"The gut microbiome in human immunodeficiency virus infection","volume":"14","author":"Zilberman-Schapira","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.trsl.2016.12.007_bib79","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3389\/fimmu.2016.00228","article-title":"Mucosal regulatory T Cells and T Helper 17 cells in HIV-associated immune activation","volume":"7","author":"Pandiyan","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2016.12.007_bib80","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1097\/QAD.0b013e3283112d29","article-title":"Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy","volume":"22","author":"Marchetti","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.trsl.2016.12.007_bib81","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12981-016-0103-1","article-title":"Gut barrier structure, mucosal immunity and intestinal microbiota in the pathogenesis and treatment of HIV infection","volume":"13","author":"Tincati","year":"2016","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.trsl.2016.12.007_bib82","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1089\/aid.2013.0280","article-title":"Microbial translocation and cardiometabolic risk factors in HIV infection","volume":"30","author":"Tr\u00f8seid","year":"2014","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.trsl.2016.12.007_bib83","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1097\/QAD.0000000000000565","article-title":"Plaque burden in HIV-infected patients is associated with serum intestinal microbiota-generated trimethylamine","volume":"29","author":"Srinivasa","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.trsl.2016.12.007_bib84","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nm.3145","article-title":"Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis","volume":"19","author":"Koeth","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.trsl.2016.12.007_bib85","doi-asserted-by":"publisher","first-page":"193ra91","DOI":"10.1126\/scitranslmed.3006438","article-title":"Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism","volume":"5","author":"Vujkovic-Cvijin","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.trsl.2016.12.007_bib86","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1056\/NEJMra041811","article-title":"Cardiovascular risk and body fat abnormalities in HIV-infected adults","volume":"352","author":"Grinspoon","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2016.12.007_bib87","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","article-title":"Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study","volume":"353","author":"Carr","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.trsl.2016.12.007_bib88","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/j.1468-1293.2007.00470.x","article-title":"Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy","volume":"8","author":"Riddler","year":"2007","journal-title":"HIV Med"},{"key":"10.1016\/j.trsl.2016.12.007_bib89","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/QAI.0b013e318164227f","article-title":"Regional adipose tissue and lipid and lipoprotein levels in HIV-infected women","volume":"48","author":"Currier","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.trsl.2016.12.007_bib90","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1097\/00002030-200305230-00010","article-title":"Cardiovascular disease risk factors in HIV patients\u2013association with antiretroviral therapy. Results from the DAD study","volume":"17","author":"Friis-M\u00f8ller","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.trsl.2016.12.007_bib91","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/j.1468-1293.2006.00400.x","article-title":"Prevalence of risk\u00a0factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study","volume":"7","author":"Glass","year":"2006","journal-title":"HIV Med"},{"key":"10.1016\/j.trsl.2016.12.007_bib92","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/00002030-199903110-00004","article-title":"Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy","volume":"13","author":"Gervasoni","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.trsl.2016.12.007_bib93","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/00126334-200001010-00005","article-title":"Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection","volume":"23","author":"Mulligan","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.trsl.2016.12.007_bib94","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/003655400750045196","article-title":"Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment","volume":"32","author":"Penzak","year":"2000","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.trsl.2016.12.007_bib95","first-page":"69","article-title":"Lipid profiles\u00a0of\u00a0Thai adult HIV-infected patients receiving protease inhibitors","volume":"38","author":"Hiransuthikul","year":"2007","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"10.1016\/j.trsl.2016.12.007_bib96","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/eurheartj\/ehr456","article-title":"Acute coronary syndromes in human immunodeficiency virus patients: a meta-analysis investigating adverse event rates and the role of antiretroviral therapy","volume":"33","author":"D'Ascenzo","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.trsl.2016.12.007_bib97","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1089\/088922203766774487","article-title":"Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors","volume":"19","author":"Coplan","year":"2003","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.trsl.2016.12.007_bib98","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/S0140-6736(02)11672-2","article-title":"Protease inhibitors and cardiovascular outcomes in patients with HIV-1","volume":"360","author":"Holmberg","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.trsl.2016.12.007_bib99","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1093\/jac\/dkv494","article-title":"Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients","volume":"71","author":"Calza","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.trsl.2016.12.007_bib100","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/135965350501000511","article-title":"Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study","volume":"10","author":"Young","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1016\/j.trsl.2016.12.007_bib101","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.3851\/IMP1675","article-title":"Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men","volume":"15","author":"Randell","year":"2010","journal-title":"Antivir Ther"},{"key":"10.1016\/j.trsl.2016.12.007_bib102","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1310\/hct1305-256","article-title":"Effect of darunavir on lipid profile in HIV-infected patients","volume":"13","author":"Overton","year":"2012","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.trsl.2016.12.007_bib103","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/j.1468-1293.2011.00941.x","article-title":"Randomized comparison of metabolic and renal effects of saquinavir\/r or atazanavir\/r plus tenofovir\/emtricitabine in treatment-na\u00efve HIV-1-infected patients","volume":"12","author":"Vrouenraets","year":"2011","journal-title":"HIV Med"},{"key":"10.1016\/j.trsl.2016.12.007_bib104","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3851\/IMP3051","article-title":"Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels: the D:A:D study","volume":"21","author":"Kamara","year":"2016","journal-title":"Antivir Ther"},{"key":"10.1016\/j.trsl.2016.12.007_bib105","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1097\/00002030-200208160-00003","article-title":"Indinavir inhibits sterol-regulatory element-binding protein-1c-dependent lipoprotein lipase and fatty acid synthase gene activations","volume":"16","author":"Miserez","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.trsl.2016.12.007_bib106","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/nm1201-1327","article-title":"HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia","volume":"7","author":"Liang","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.trsl.2016.12.007_bib107","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1046\/j.1365-2362.2002.00989.x","article-title":"LDL-receptors expression in HIV-infected patients: relations to antiretroviral therapy, hormonal status, and presence of lipodystrophy","volume":"32","author":"Petit","year":"2002","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.trsl.2016.12.007_bib108","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/S0140-6736(98)03391-1","article-title":"Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance","volume":"351","author":"Carr","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.trsl.2016.12.007_bib109","doi-asserted-by":"publisher","first-page":"e59514","DOI":"10.1371\/journal.pone.0059514","article-title":"HIV protease inhibitors disrupt lipid metabolism by activating endoplasmic reticulum stress and inhibiting autophagy activity in adipocytes","volume":"8","author":"Zha","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2016.12.007_bib110","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1097\/QAD.0b013e328359b8be","article-title":"The protease inhibitor atazanavir triggers autophagy and mitophagy in human preadipocytes","volume":"26","author":"Gibellini","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.trsl.2016.12.007_bib111","doi-asserted-by":"publisher","first-page":"20251","DOI":"10.1074\/jbc.C000228200","article-title":"The mechanism of insulin resistance caused by HIV protease inhibitor therapy","volume":"275","author":"Murata","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.trsl.2016.12.007_bib112","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/00002030-200204120-00005","article-title":"Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations","volume":"16","author":"Murata","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.trsl.2016.12.007_bib113","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3844\/ajidsp.2006.187.192","article-title":"Molecular mechanisms for altered glucose homeostasis in HIV infection","volume":"2","author":"Hruz","year":"2006","journal-title":"Am J Infect Dis"},{"key":"10.1016\/j.trsl.2016.12.007_bib114","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.2337\/diabetes.50.6.1425","article-title":"The HIV protease\u00a0inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes","volume":"50","author":"Rudich","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.trsl.2016.12.007_bib115","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1097\/01.aids.0000244200.11006.55","article-title":"Effects of atazanavir\/ritonavir and lopinavir\/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in\u00a0vitro and clinically","volume":"20","author":"Noor","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.trsl.2016.12.007_bib116","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/01.qai.0000176654.97392.c7","article-title":"Direct comparison of the acute in\u00a0vivo effects of HIV protease inhibitors on peripheral glucose disposal","volume":"40","author":"Yan","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.trsl.2016.12.007_bib117","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1089\/aid.2011.0327","article-title":"Metabolic effects of darunavir\/ritonavir versus atazanavir\/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks","volume":"28","author":"Aberg","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.trsl.2016.12.007_bib118","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1080\/15284336.2016.1141468","article-title":"Effects of once-daily darunavir\/ritonavir versus atazanavir\/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial","volume":"17","author":"Overton","year":"2016","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.trsl.2016.12.007_bib119","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1056\/NEJMoa051871","article-title":"Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV","volume":"354","author":"Gallant","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2016.12.007_bib120","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and Safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive Patients: A 3-year randomized trial","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.trsl.2016.12.007_bib121","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/QAI.0000000000001186","article-title":"Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected adults with renal impairment","volume":"74","author":"Post","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.trsl.2016.12.007_bib122","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/01.qai.0000182230.47819.aa","article-title":"Fat distribution in men with HIV infection","volume":"40","author":"Bacchetti","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.trsl.2016.12.007_bib123","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1097\/QAD.0b013e32833ac7a2","article-title":"Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy","volume":"24","author":"Grunfeld","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.trsl.2016.12.007_bib124","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/QAI.0b013e31814b94e2","article-title":"Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study","volume":"46","author":"Grunfeld","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.trsl.2016.12.007_bib125","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1080\/09540121.2010.543885","article-title":"Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study","volume":"23","author":"Lake","year":"2011","journal-title":"AIDS Care"},{"key":"10.1016\/j.trsl.2016.12.007_bib126","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/cid\/ciu234","article-title":"Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials","volume":"59","author":"Tebas","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trsl.2016.12.007_bib127","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1086\/498505","article-title":"Body fat and other\u00a0metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients","volume":"42","author":"Jemsek","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trsl.2016.12.007_bib128","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1093\/jac\/dkv195","article-title":"A randomized, controlled trial of the effect of rilpivirine versus efavirenz on cardiovascular risk in healthy volunteers","volume":"70","author":"Gupta","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.trsl.2016.12.007_bib129","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1097\/00002030-199905070-00009","article-title":"Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine","volume":"13","author":"Mart\u00ednez","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.trsl.2016.12.007_bib130","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.2337\/dc07-2013","article-title":"Incidence and risk factors for new-onset diabetes in HIV-infected patients: the data collection on adverse events of anti-HIV drugs (D: A:D) study","volume":"31","author":"De Wit","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.trsl.2016.12.007_bib131","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s40261-014-0266-2","article-title":"Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks","volume":"35","author":"Quercia","year":"2015","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.trsl.2016.12.007_bib132","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1179\/1945577115Y.0000000002","article-title":"Effects of raltegravir combined with tenofovir\/emtricitabine on body shape, bone density, and lipids in African-Americans initiating HIV therapy","volume":"16","author":"Young","year":"2015","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.trsl.2016.12.007_bib133","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3851\/IMP3049","article-title":"Neither boosted elvitegravir\u00a0nor darunavir with emtricitabine\/tenofovir disoproxil fumarate increase insulin resistance in healthy volunteers: results from the STRIBILD-IR study","volume":"21","author":"Spinner","year":"2016","journal-title":"Antivir Ther"},{"key":"10.1016\/j.trsl.2016.12.007_bib134","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1093\/jac\/dks539","article-title":"Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial","volume":"68","author":"Bonjoch","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.trsl.2016.12.007_bib135","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1530\/EJE-14-0337","article-title":"Prevalence of insulin resistance and risk of diabetes mellitus in HIV-infected patients receiving current antiretroviral drugs","volume":"171","author":"Araujo","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.trsl.2016.12.007_bib136","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/QAD.0b013e32834e8776","article-title":"Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment","volume":"26","author":"Capeau","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.trsl.2016.12.007_bib137","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1001\/archinte.165.10.1179","article-title":"Antiretroviral therapy and the\u00a0prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study","volume":"165","author":"Brown","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.trsl.2016.12.007_bib138","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1097\/QAD.0b013e32827038d0","article-title":"Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study","volume":"21","author":"Tien","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.trsl.2016.12.007_bib139","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1111\/dme.12455","article-title":"Incidence of diabetes mellitus in a population-based cohort of HIV-infected and non-HIV-infected persons: the impact of clinical and therapeutic factors over time","volume":"31","author":"Tripathi","year":"2014","journal-title":"Diabet Med"},{"key":"10.1016\/j.trsl.2016.12.007_bib140","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1097\/QAD.0b013e32832bd7af","article-title":"HIV infection and the risk of diabetes mellitus","volume":"23","author":"Butt","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.trsl.2016.12.007_bib141","doi-asserted-by":"publisher","first-page":"e44575","DOI":"10.1371\/journal.pone.0044575","article-title":"Risk of diabetes mellitus in persons with and without HIV: a Danish nationwide population-based cohort study","volume":"7","author":"Rasmussen","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2016.12.007_bib142","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s10654-012-9707-5","article-title":"Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy","volume":"27","author":"Galli","year":"2012","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.trsl.2016.12.007_bib143","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3851\/IMP1711","article-title":"Incident hyperglycaemia among older adults with or at-risk for HIV infection","volume":"16","author":"Polsky","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.trsl.2016.12.007_bib144","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1086\/523577","article-title":"Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity?","volume":"45","author":"Goulet","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trsl.2016.12.007_bib145","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/00126334-200303010-00009","article-title":"Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women","volume":"32","author":"Justman","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.trsl.2016.12.007_bib146","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1086\/518619","article-title":"Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV cohort study","volume":"45","author":"Ledergerber","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trsl.2016.12.007_bib147","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/j.1468-1293.2007.00499.x","article-title":"Hepatitis C is associated with type 2 diabetes mellitus in HIV-infected persons without traditional risk factors","volume":"8","author":"Jain","year":"2007","journal-title":"HIV Med"},{"key":"10.1016\/j.trsl.2016.12.007_bib148","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1097\/00126334-200308150-00005","article-title":"The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons","volume":"33","author":"Mehta","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.trsl.2016.12.007_bib149","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/j.1468-1293.2008.00687.x","article-title":"Risk factors for incident diabetes mellitus among HIV-infected patients receiving combination antiretroviral therapy in Taiwan: a case-control study","volume":"10","author":"Lo","year":"2009","journal-title":"HIV Med"},{"key":"10.1016\/j.trsl.2016.12.007_bib150","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/cid\/cis489","article-title":"HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals","volume":"55","author":"Lang","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trsl.2016.12.007_bib151","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/QAI.0000000000000009","article-title":"Immunodeficiency and risk of myocardial infarction among HIV-positive individuals with access to care","volume":"65","author":"Silverberg","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.trsl.2016.12.007_bib152","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.thromres.2014.05.037","article-title":"Prognostic indicators for recurrent thrombotic events in HIV-infected patients with acute coronary syndromes: use of registry data from 12 sites in Europe, South Africa and the United States","volume":"134","author":"D'Ascenzo","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.trsl.2016.12.007_bib153","doi-asserted-by":"publisher","first-page":"53E","DOI":"10.1016\/j.amjcard.2005.06.006","article-title":"Recent National cholesterol Education program adult treatment panel III update: adjustments and options","volume":"96","author":"Stone","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.trsl.2016.12.007_bib154","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.1468-1293.2006.00362.x","article-title":"The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study","volume":"7","author":"Law","year":"2006","journal-title":"HIV Med"},{"key":"10.1016\/j.trsl.2016.12.007_bib155","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1097\/QAD.0000000000001163","article-title":"Cardiovascular disease risk scores' relationship to subclinical cardiovascular disease among HIV-infected and HIV-uninfected men","volume":"30","author":"Monroe","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.trsl.2016.12.007_bib156","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/15284336.2016.1177266","article-title":"The Framingham function overestimates the risk of ischemic heart disease in HIV-infected patients from Barcelona","volume":"17","author":"Herrera","year":"2016","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.trsl.2016.12.007_bib157","first-page":"43","article-title":"Cardiovascular risk assessment in HIV-infected male patients: a comparison of Framingham, SCORE, PROCAM and DAD risk equations","volume":"23","author":"Pir\u0161","year":"2014","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"10.1016\/j.trsl.2016.12.007_bib158","doi-asserted-by":"publisher","first-page":"19515","DOI":"10.7448\/IAS.17.4.19515","article-title":"Cardiovascular risk evaluation of HIV-positive patients in a case-control study: comparison of the D:A:D and Framingham equations","volume":"17","author":"Markowicz","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.trsl.2016.12.007_bib159","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1093\/cid\/ciw564","article-title":"Baseline, time-updated, and cumulative HIV care metrics for predicting acute myocardial infarction and all-cause mortality","volume":"63","author":"Salinas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trsl.2016.12.007_bib160","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1093\/cid\/ciw615","article-title":"Cardiovascular disease risk prediction in the HIV Outpatient Study","volume":"63","author":"Thompson-Paul","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trsl.2016.12.007_bib161","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1093\/jac\/dkw346","article-title":"Prediction of hard cardiovascular events in HIV patients","volume":"71","author":"Raggi","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.trsl.2016.12.007_bib162","article-title":"Estimating longitudinal risks and benefits from cardiovascular preventive therapies among medicare patients: The Million Hearts longitudinal ASCVD risk assessment tool","author":"Lloyd-Jones","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2016.12.007_bib163","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1093\/cid\/civ014","article-title":"Declining relative risk for myocardial infarction among HIV-positive compared with HIV-negative individuals with access to care","volume":"60","author":"Klein","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trsl.2016.12.007_bib164","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/cid\/ciw289","article-title":"Statin utilization and recommendations among HIV- and HCV-infected veterans: a cohort study","volume":"63","author":"Clement","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trsl.2016.12.007_bib165","article-title":"Statin use with the ATP III guidelines compared to the 2013 ACC\/AHA guidelines in HIV primary care patients","author":"Elsamadisi","year":"2015","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.trsl.2016.12.007_bib166","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.2337\/diabetes.51.10.3120","article-title":"Components of the \u201cmetabolic syndrome\u201d and incidence of type 2 diabetes","volume":"51","author":"Hanson","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.trsl.2016.12.007_bib167","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jacc.2006.09.032","article-title":"Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies","volume":"49","author":"Gami","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.trsl.2016.12.007_bib168","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1001\/archinte.167.7.642","article-title":"Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity","volume":"167","author":"McLaughlin","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.trsl.2016.12.007_bib169","doi-asserted-by":"publisher","first-page":"722","DOI":"10.7326\/0003-4819-143-10-200511150-00009","article-title":"The metabolic syndrome as a predictor of nonalcoholic fatty liver disease","volume":"143","author":"Hamaguchi","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trsl.2016.12.007_bib170","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1164\/ajrccm.165.5.2103001","article-title":"Obstructive sleep apnea is independently associated with insulin resistance","volume":"165","author":"Ip","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.trsl.2016.12.007_bib171","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijcard.2016.08.324","article-title":"Metabolic syndrome and its individual components with mortality among patients with coronary heart disease","volume":"224","author":"Chen","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.trsl.2016.12.007_bib172","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/eurheartj\/ehl524","article-title":"The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns","volume":"28","author":"Wang","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.trsl.2016.12.007_bib173","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1053\/meta.2002.29999","article-title":"Elevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in human immunodeficiency virus-infected subjects with fat redistribution","volume":"51","author":"Meininger","year":"2002","journal-title":"Metabolism"},{"key":"10.1016\/j.trsl.2016.12.007_bib174","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1071\/SH14084","article-title":"Changes in the prevalence of lipodystrophy, metabolic syndrome and cardiovascular disease risk in HIV-infected men","volume":"12","author":"Price","year":"2015","journal-title":"Sex Health"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524416304662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524416304662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T20:51:38Z","timestamp":1658263898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524416304662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":174,"alternative-id":["S1931524416304662"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2016.12.007","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HIV and its relationship to insulin resistance and lipid abnormalities","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2016.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}